Mequitazine

Mequitazine

Clinical data
Trade names	Primalan
AHFS/Drugs.com	International Drug Names
ATC code	R06AD07 (WHO)
Legal status
Legal status	EU: Rx-only
Identifiers
IUPAC name 10-(1-Azabicyclo[2.2.2]octan-3-ylmethyl)phenothiazine
CAS Number	29216-28-2 Y
PubChem CID	4066
DrugBank	DB01071 N
ChemSpider	3926 N
UNII	Y463242LY2
KEGG	D01324 Y
CompTox Dashboard (EPA)	DTXSID8023262
ECHA InfoCard	100.045.005
Chemical and physical data
Formula	C20H22N2S
Molar mass	322.47 g·mol−1
3D model (JSmol)	Interactive image
SMILES c1ccc2c(c1)Sc1ccccc1N2CC1CN2CCC1CC2
InChI InChI=1S/C20H22N2S/c1-3-7-19-17(5-1)22(18-6-2-4-8-20(18)23-19)14-16-13-21-11-9-15(16)10-12-21/h1-8,15-16H,9-14H2 Key:HOKDBMAJZXIPGC-UHFFFAOYSA-N
NY (what is this?)  (verify)

Mequitazine (trade name Primalan) is an H₁ antagonist and anticholinergic of the phenothiazine chemical class. It is used to treat allergies and rhinitis.

It was patented in 1969 and came into medical use in 1976.

Contraindications

Severe liver disease; premature infants or full-term neonates.

Special precautions

Pregnancy, lactation; severe cardiovascular disorders; asthma; angle-closure glaucoma, urinary retention, prostatic hyperplasia, pyloroduodenal obstruction; renal and hepatic impairment; elderly, children; epilepsy. May impair ability to drive or operate machinery.

Adverse reactions

CNS depression including slight drowsiness to deep sleep, lassitude, dizziness, incoordination. Headache, psychomotor impairment and antimuscarinic effects. Rarely, rashes and hypersensitivity reactions, blood disorders, convulsions, sweating, myalgia, paraesthesias, extrapyramidal effects, tremor, confusion, sleep and GI disturbances, tinnitus, hypotension, hair loss. Photosensitivity, jaundice.

Drug interactions

Enhances effects of CNS depressants e.g. alcohol, barbiturates, hypnotics, opioid analgesics, anxiolytics and antipsychotics. Can mask signs of ototoxicity caused by aminoglycosides. QT prolongation (which can lead to torsades de pointes arrhythmia) reported with spiramycin.

Further reading

• Ramírez Chanona N, del Rio Navarro BE, Pérez Martín J (November–December 2005). "[Efficacy of mequitazine (Primalan) on the relief of symptoms of allergic rhinoconjunctivitis in children. Documented clinical experience]". Revista Alergia Mexico (in Spanish). 52 (6): 221–5. PMID 16568706.
• Theunissen EL, Vermeeren A, van Oers AC, van Maris I, Ramaekers JG (February 2004). "A dose-ranging study of the effects of mequitazine on actual driving, memory and psychomotor performance as compared to dexchlorpheniramine, cetirizine and placebo". Clinical and Experimental Allergy. 34 (2): 250–8. doi:10.1111/j.1365-2222.2004.01874.x. PMID 14987305. S2CID 23019669.
• Nakamura K, Yokoi T, Kodama T, Inoue K, Nagashima K, Shimada N, et al. (February 1998). "Oxidation of histamine H1 antagonist mequitazine is catalyzed by cytochrome P450 2D6 in human liver microsomes" (PDF). The Journal of Pharmacology and Experimental Therapeutics. 284 (2): 437–42. PMID 9454781.
• Persi L, Dupin O, Arnaud B, Trinquand C, Michel FB, Bousquet J (April 1997). "Efficacy of mequitazine in comparison with placebo assessed by ocular challenge with allergen in allergic conjunctivitis". Allergy. 52 (4): 451–4. doi:10.1111/j.1398-9995.1997.tb01028.x. PMID 9188930. S2CID 34785561.

External links

• "Mequitazine". Drug Information Portal. U.S. National Library of Medicine.